对高脂肪饮食养小鼠的胰岛素耐药性进行二甲二硫化物管理的影响
Takamasa Tsuzuki1, Takayuki Negishi1, Kazunori Yukawa1
1Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan.
Nutrition (Burbank, Los Angeles County, Calif.)
|December 2, 2023
概括
来自大的二二硫化物 (DADS) 在肥胖小鼠中改善了胰岛素抵抗. 这种天然化合物减少了身体脂肪和肝脏脂肪,可能是通过热冲击蛋白72激活.
科学领域:
- 代谢研究的研究.
- 药理学 药理学是指药理学的学科.
- 肥胖研究的研究.
背景情况:
- 双二硫化物 (DADS) 是一种来自大的有机硫化合物,具有已知的药理作用.
- DADS对肥胖引起的胰岛素抵抗 (IR) 的影响及其机制尚未完全理解.
研究的目的:
- 为了研究DADS对饮食诱导肥胖的小鼠系统性IR的影响.
- 在这个模型中探索DADS作用的潜在分子机制.
主要方法:
- 雄性C57BL/6J小鼠被食高脂肪饮食以诱导肥胖.
- 小鼠接受口服DADS (25或100毫克/公斤) 或载体5天/周,持续8周.
- 进行葡萄糖耐受性测试 (GTT) 和胰岛素耐受性测试 (ITT);分析肝脏和脂肪组织.
主要成果:
- DADS的剂量依赖性改善了全身胰岛素抵抗 (ITT).
- 随着高剂量的DADS.观察到体重增加,脂肪重量和肝脏三糖醇的显著减少.
- 高剂量的DADS降低了JNK酸化,并在肝脏中增加了HSP72的表达.
结论:
- DADS有效地减轻肥胖小鼠的全身胰岛素抵抗.
- 潜在的机制包括减少肝脏脂肪积累和HSP72介导的JNK信号的抑制.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
Insulin: Dosing Regimen and Adverse Effects
181
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
181


